http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005115469-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1c645827d533505e4bbd3c1ac7debdb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e29526f284c0155fd79806c9dd5a1c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c48ea9af3d9b3b39889111baa0e33b4f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
| filingDate | 2005-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca5752181af2ec9acac358a9e653fb2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e4f32d0283247a1f780c16312ab857d |
| publicationDate | 2005-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005115469-A2 |
| titleOfInvention | Estrogen modulation of ifn-gamma-mediated conditions and diseases |
| abstract | Particular aspects provide methods for: modulating IFN-Ϝ-mediated conditions and diseases (e.g. inflammation, HIV/AIDS, etc). Additionally provided are methods for: reducing IFN-Ϝ expression or secretion in cultured mammalian cells, comprising culturing in the presence of at least one agent selected from the group consisting of estrogen, estriol, estrone and a SERM; for ex-vivo therapy for an IFN-Ϝ-mediated condition or disease, comprising culturing isolated lymphoid cells in the presence of at least one of the above agents; for treating an IFN-Ϝ-mediated condition or disease in a mammal, comprising administering to a subject at least one at least one of the above agents; for treating an IFN-Ϝ-mediated condition or disorder in a gender-dependent manner; for conferring estrogen-responsive expression using a recombinant SNP IFN-Ϝ-179G/T promoter; and for gene therapy using same. Preferably, mammalian cells are human, selected from T cells, PBL, LPMC, and combinations thereof. In particular aspects, the cells are female. |
| priorityDate | 2004-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 328.